IMTXImmatics N.V.

HealthcareUSD
$9.43

The financials

Immatics N.V. by the numbers

Immatics N.V. income statement, H2 2025 against the same quarter a year earlier
Income statementH2 2025Q2 2024Change
Operating income−€94M−€27Mn/a
Net income−€86M−€18Mn/a
Diluted EPS−€0.70−€0.17n/a

Biotechnology

Ranks #143 of 145 by Smart Score

Compare peers
COAG-3.6%
Hemab Therapeutics Holdings, Inc.
AVLN-3.7%
Avalyn Pharma Inc.
JBIO-0.41%
Jade Biosciences, Inc.
SVRA+3.4%
Savara Inc.
DMRA+2.6%
Damora Therapeutics, Inc.
MNKD+2.3%
MannKind Corporation